Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalirudin vs Enoxaparin in Critically Ill COVID-19
NCT05334654Phase 2Completed
- Sponsor
- University of Magna Graecia
- Start
- Apr 2022
- Primary completion
- Jun 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bivalirudin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Magna Graecia. Primary endpoint: Time spent under invasive mechanical ventilation at 28 days. Started Apr 2022; status: completed.
02
Drugs
bivalirudin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05334654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05334654.